Semaglutide: GLP-1 Receptor Agonist ā Up to 15% Body Weight Reduction in 68-Week Trials
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that reduces appetite, slows gastric emptying, and improves insulin sensitivity through activation of GLP-1 receptors in the brain, gut, and pancreas ā producing clinically significant weight reduction in overweight and obese adults.
Semaglutide is not a new compound. It has an established pharmaceutical history as Ozempic (for type 2 diabetes management) and Wegovy (for chronic weight management), both FDA-approved. At the doses used for weight management in the STEP trials, semaglutide produced a mean weight reduction of approximately 14.9% of body weight over 68 weeks in adults without diabetes ā the largest weight reduction documented in a pharmacological trial at the time of its approval.
At Rebuild Regen Medical Clinic, semaglutide is prescribed for weight management in patients with clinical indications (obesity, overweight with weight-related comorbidities) where the evidence supports the intervention. No semaglutide prescription is issued without a metabolic baseline evaluation.
What Semaglutide Is ā GLP-1 Mechanism and Metabolic Effect
GLP-1 is an endogenous incretin hormone secreted by L-cells in the small intestine after eating. Its natural functions include stimulating insulin release from the pancreas, suppressing glucagon, slowing gastric emptying, and signaling satiety to the brain's appetite centers. Endogenous GLP-1 has a half-life of approximately 2 minutes ā degraded rapidly by DPP-IV enzymes.
Semaglutide is a synthetic GLP-1 analog with structural modifications that resist DPP-IV degradation, extending its half-life to approximately 7 days with subcutaneous injection. This sustained GLP-1 receptor activation produces the metabolic effects at a continuous level rather than only during and after meals.
The primary mechanisms relevant to weight management:
Central appetite suppression: GLP-1 receptors in the hypothalamus and brainstem (particularly the nucleus tractus solitarius) reduce appetite signaling when activated. Semaglutide crosses the blood-brain barrier and directly activates these receptors, producing a sustained reduction in caloric drive that most patients describe as the absence of constant hunger rather than active suppression.
Gastric emptying delay: Slowing the rate at which the stomach empties extends the satiety signal from food. Patients eat less because they feel full faster and stay full longer.
Insulin secretion enhancement / glucagon suppression: In the pancreas, GLP-1 receptor activation stimulates insulin release in response to glucose and suppresses glucagon, improving insulin sensitivity and glycemic control. This mechanism is the basis for semaglutide's anti-diabetic applications.
Clinical Applications
Weight management: The primary application. Patients with a BMI of 30 or above, or 27 or above with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea, or fatty liver disease), are candidates for evaluation.
Type 2 diabetes support: Glycemic control improvement and potential for A1c reduction in patients with type 2 diabetes or prediabetes. Elizabeth coordinates with the patient's primary care or endocrinology provider when diabetes is a primary diagnosis.
Metabolic syndrome: Patients with the cluster of metabolic syndrome features ā central obesity, insulin resistance, elevated triglycerides, low HDL, elevated blood pressure ā benefit from the comprehensive metabolic effect of semaglutide beyond weight reduction alone.
Cardiovascular risk reduction: The SELECT trial demonstrated cardiovascular event reduction in overweight/obese adults without diabetes, expanding semaglutide's evidence base beyond glycemic and weight outcomes.
Protocol at Rebuild Regen
Elizabeth requires a metabolic baseline before initiating semaglutide:
- Fasting glucose, HbA1c, fasting insulin
- Lipid panel
- Comprehensive metabolic panel (liver and kidney function)
- Thyroid panel (to rule out thyroid pathology as a contributing factor)
- Weight, BMI, waist circumference
Semaglutide is initiated at the lowest effective dose (0.25 mg subcutaneous weekly) and titrated over 4 to 16 weeks to the target dose based on tolerability and response. Elizabeth monitors for GI side effects (nausea, constipation ā common during titration) and adjusts the titration schedule accordingly.
Ongoing monitoring is quarterly for the first year ā metabolic labs, weight, blood pressure, and clinical review.
Frequently Asked Questions
Is semaglutide the same as Ozempic or Wegovy?
Semaglutide is the active ingredient in both Ozempic (approved for type 2 diabetes at doses up to 1 mg) and Wegovy (approved for chronic weight management at doses up to 2.4 mg). The compound is identical; the approved indication and dosing differ. Compounded semaglutide from FDA-registered compounding pharmacies is available and what Elizabeth prescribes in this setting.
What are the most common side effects?
Nausea during dose titration is the most reported side effect and is the primary reason the slow titration schedule is used. Nausea typically diminishes after 4 to 8 weeks at any given dose level. Constipation, reduced appetite (expected), and mild fatigue are also reported. GI side effects are manageable with appropriate titration pace and dietary guidance.
How much weight loss should I expect?
The STEP clinical trials showed a mean of approximately 15% body weight reduction over 68 weeks in adults without diabetes using semaglutide 2.4 mg weekly. Individual results vary significantly based on diet, activity, starting weight, and adherence. Semaglutide is a tool that works best with appropriate dietary support.
When Semaglutide Is Not Appropriate
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), history of pancreatitis, severe renal impairment, and pregnancy. Patients with severe GI motility disorders may not tolerate the gastric emptying effects. Elizabeth screens for all relevant contraindications before prescribing.
Rebuild Regen Medical Clinic 3320 N Federal Hwy #101, Lighthouse Point, FL 33064 (954) 953-4208 | rebuildregenmedical.com
Back to Peptide Therapy | Tirzepatide | Schedule a Consultation
Ready to Start Your Recovery?
Schedule a consultation with Rebuild Regen Medical Clinic in Lighthouse Point, FL.